ArticleNature2017
Genomic hallmarks of localized, non-indolent prostate cancer.
Abstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 376 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
376citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
376 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aging and prostate health: meta-analytic insights into age-related prostatic disorders.Frontiers in oncology · 2026Pooled it
- Phase II Randomized Study of MK-2206 and Bicalutamide in Prostate Cancer Patients With Rising PSA After Primary Therapy (ECOG-ACRIN E2809).The Prostate · 2026Trial
- Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.Cell reports. Medicine · 2025Trial
- A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.Nature cancer · 2022Trial
- The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer.Nature communications · 2026Article
- Oligometastatic prostate cancer - bridging the gap between localized and metastatic disease.Nature reviews. Urology · 2026Review
- PGC1α-mediated upregulation of PHD2 represses HIF-signaling, limiting prostate cancer progression.Cell death and differentiation · 2026Article
- Article
- A pathological morphology parameter-based prognostic nomogram for high-risk prostate cancer patients treated with neoadjuvant therapy followed by radical prostatectomy: a retrospective study.World journal of surgical oncology · 2026Article
- Article
- Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.BMC genomic data · 2026Article
- Loss of UFL1 drives chromosome instability and tumorigenesis of prostate cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Single base focal hypermutation cooccurs with structural variation as an early event in advanced prostate tumourigenesis with ancestry specific independence: a multi-ancestral observational study.Genome medicine · 2026Observational
- Landscape of Allele-Specific Expression in Prostate Cancer Reveals Recurrent, Stage-Specific Events in AR Signaling and Resistance Pathways.Molecular cancer research : MCR · 2026Article
- Identification of non-canonical peptides with moPepGen.Nature biotechnology · 2026Article
- Review
- Targeting pre-existing club-like cells in prostate cancer potentiates androgen deprivation therapy.EMBO molecular medicine · 2026Article
- Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.Journal of the National Cancer Center · 2026Review
- Gene-body DNA methylation of ONECUT2 predicts its expression and prostate cancer aggressiveness in needle biopsies.Biomarker research · 2026Article
- Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution.International journal of cancer · 2026Review
316 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
70 authors.
Michael FraserPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Veronica Y SabelnykovaInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Takafumi N YamaguchiInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Lawrence E HeislerInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Julie LivingstoneInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Vincent HuangInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Yu-Jia ShiahInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Fouad YousifInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Xihui LinInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Andre P MasellaInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Natalie S FoxInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Michael XieInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Stephenie D ProkopecInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Alejandro BerlinDepartment of Radiation Oncology, University of Toronto, Toronto, Canada.
Emilie LalondeInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Musaddeque AhmedPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Dominique TrudelDepartment of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, Canada.
Xuemei LuoInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Timothy A BeckInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Alice MengPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Junyan ZhangPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Alister D'CostaInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Robert E DenrocheInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Haiying KongInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Shadrielle Melijah G EspirituInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Melvin L K ChuaDepartment of Radiation Oncology, University of Toronto, Toronto, Canada.
Ada WongGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Taryne ChongGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Michelle SamGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Jeremy JohnsGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Lee TimmsGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Nicholas B BuchnerGenome Technologies Program, Ontario Institute for Cancer Research, Toronto, Canada.
Michèle OrainDepartment of Pathology and Research Centre of CHU de Québec-Université Laval. Québec City, Canada.
Valérie PicardDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.
Helène HovingtonDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.
Alexander MurisonPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Ken KronPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Nicholas J HardingInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Christine P'ngInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Kathleen E HoulahanInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Kenneth C ChuInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Bryan LoInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Francis NguyenInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Constance H LiInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Ren X SunInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Richard de BorjaInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Christopher I CooperInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Julia F HopkinsInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Shaylan K GovindInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Clement FungInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Daryl WaggottInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Jeffrey GreenInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Syed HaiderInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Michelle A Chan-Seng-YueInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Esther JungInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Zhiyuan WangInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Alain BergeronDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.
Alan Dal PraDepartment of Radiation Oncology, University of Toronto, Toronto, Canada.
Louis LacombeDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.
Colin C CollinsDepartment of Urologic Sciences, University of British Columbia, Vancouver, Canada.
Cenk SahinalpSchool of Computing Science, Simon Fraser University, Burnaby, Canada.
Mathieu LupienPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Neil E FleshnerDivision of Urology, Princess Margaret Cancer Centre/University Health Network, Toronto, Canada.
Housheng H HePrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Yves FradetDivision of Urology and Research Centre of CHU de Québec-Université Laval, Québec City, Canada.
Bernard TetuDepartment of Pathology and Research Centre of CHU de Québec-Université Laval. Québec City, Canada.
Theodorus van der KwastDepartment of Pathology and Laboratory Medicine, Toronto General Hospital/University Health Network, Toronto, Canada.
John D McPhersonDepartment of Medical Biophysics, University of Toronto, Toronto, Canada.
Robert G BristowPrincess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Paul C BoutrosInformatics &Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate tumours are highly variable in their response to therapies, but clinically available prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 whole-genome sequences and 277 additional whole-exome sequences from localized, non-indolent prostate tumours with similar clinical risk profiles, and carried out RNA and methylation analyses in a subset. These tumours had a paucity of clinically actionable single nucleotide variants, unlike those seen in metastatic disease. Rather, a significant proportion of tumours harboured recurrent non-coding aberrations, large-scale genomic rearrangements, and alterations in which an inversion repressed transcription within its boundaries. Local hypermutation events were frequent, and correlated with specific genomic profiles. Numerous molecular aberrations were prognostic for disease recurrence, including several DNA methylation events, and a signature comprised of these aberrations outperformed well-described prognostic biomarkers. We suggest that intensified treatment of genomically aggressive localized prostate cancer may improve cure rates.
Indexed as
GenomicsMutationChromothripsisDNA Copy Number VariationsDNA MethylationExomeGenome, HumanHumansMaleNeoplasm MetastasisPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantRecurrence
Identifiers
PMID
28068672What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.